These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 21422415)
1. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. Jaspers HC; Verbist BM; Schoffelen R; Mattijssen V; Slootweg PJ; van der Graaf WT; van Herpen CM J Clin Oncol; 2011 Jun; 29(16):e473-6. PubMed ID: 21422415 [No Abstract] [Full Text] [Related]
2. Clinicopathologic study of salivary duct carcinoma and the efficacy of androgen deprivation therapy. Yamamoto N; Minami S; Fujii M Am J Otolaryngol; 2014; 35(6):731-5. PubMed ID: 25087467 [TBL] [Abstract][Full Text] [Related]
3. Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression-A Case Report. Sheth H; Kumar P; Shreenivas A; Sambath J; Pragya R; Madre C; Athikari N; Khandare H; Peshattiwar V; Datar R; Limaye S JCO Precis Oncol; 2021; 5():. PubMed ID: 34036229 [No Abstract] [Full Text] [Related]
4. Definitive treatment of androgen receptor-positive salivary duct carcinoma with androgen deprivation therapy and external beam radiotherapy. Soper MS; Iganej S; Thompson LD Head Neck; 2014 Jan; 36(1):E4-7. PubMed ID: 23720164 [TBL] [Abstract][Full Text] [Related]
5. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers. Locati LD; Perrone F; Cortelazzi B; Lo Vullo S; Bossi P; Dagrada G; Quattrone P; Bergamini C; Potepan P; Civelli E; Fallai C; Pilotti S; Licitra L Head Neck; 2016 May; 38(5):724-31. PubMed ID: 25522335 [TBL] [Abstract][Full Text] [Related]
6. A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocol. Weijers JAM; Verhaegh GW; Lassche G; van Engen-van Grunsven ACH; Driessen CML; van Erp NP; Jonker MA; Schalken JA; van Herpen CML BMC Cancer; 2024 Sep; 24(1):1174. PubMed ID: 39304797 [TBL] [Abstract][Full Text] [Related]
7. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Fushimi C; Tada Y; Takahashi H; Nagao T; Ojiri H; Masubuchi T; Matsuki T; Miura K; Kawakita D; Hirai H; Hoshino E; Kamata S; Saotome T Ann Oncol; 2018 Apr; 29(4):979-984. PubMed ID: 29211833 [TBL] [Abstract][Full Text] [Related]
8. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Jaehne M; Roeser K; Jaekel T; Schepers JD; Albert N; Löning T Cancer; 2005 Jun; 103(12):2526-33. PubMed ID: 15900577 [TBL] [Abstract][Full Text] [Related]
9. Circumscribed salivary duct carcinoma of the palate: a non-threatening variant. Ide F; Mishima K; Saito I Histopathology; 2004 Jul; 45(1):89-91. PubMed ID: 15228452 [No Abstract] [Full Text] [Related]
11. Complete Response of Metastatic Androgen Receptor-Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature. Arce-Salinas C; Riesco-Martinez MC; Hanna W; Bedard P; Warner E J Clin Oncol; 2016 Feb; 34(4):e21-4. PubMed ID: 24888812 [No Abstract] [Full Text] [Related]